Selective HDAC6 Inhibition Restores Axonal Transport in Preclinical ALS Models

Amyotrophic lateral sclerosis and frontotemporal dementia represent a clinical spectrum of neurodegenerative disorders characterized by the progressive, fatal loss of motor and cognitive function. At the cellular level, these conditions are driven by a complex interplay of neuroinflammation, oxidative stress, and the failure of proteostasis, the biological systems responsible for protein quality control [1, 2]. When cellular organelles fail to manage misfolded proteins, the resulting accumulation triggers neurotoxic pathways and eventual cell death [3, 4]. Histone deacetylases have emerged as critical therapeutic targets because they regulate the epigenetic and post-translational modifications that govern neuronal survival and microtubule stability [5]. While metabolic and inflammatory modulators are under investigation, the search for direct disease-modifying agents remains focused on restoring these fundamental homeostatic mechanisms. A recent study investigates a specific molecular strategy designed to address these transport and protein-handling deficits with high precision, potentially offering a new avenue for slowing disease progression.